Evidence map›Paper›PMID 35251023›Full record

ArticleFrontiers in immunology2022

Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity.

Aicha Laghmouchi, Michel G D Kester, Conny Hoogstraten, Lois Hageman, Wendy de Klerk, Wesley Huisman, Eva A S Koster, Arnoud H de Ru, Peter van Balen, Sebastian Klobuch and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Human T cells recognize HLA-DP-bound peptides in two orientations.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Aicha LaghmouchiDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Michel G D KesterDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Conny HoogstratenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Lois HagemanDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Wendy de KlerkDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Wesley HuismanDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Eva A S KosterDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Arnoud H de RuCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
Peter van BalenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Sebastian KlobuchDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Peter A van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
J H Frederik FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Inge JedemaDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Leiden University Medical Center · NLNetherlands Metabolomics Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the context of HLA-DP-mismatched allogeneic stem cell transplantation, mismatched HLA-DP alleles can provoke profound allo-HLA-DP-specific immune responses from the donor T-cell repertoire leading to graft-versus-leukemia effect and/or graft-versus-host disease in the patient. The magnitude of allo-HLA-DP-specific immune responses has been shown to depend on the specific HLA-DP disparity between donor and patient and the immunogenicity of the mismatched HLA-DP allele(s). HLA-DP peptidome clustering (DPC) was developed to classify the HLA-DP molecules based on similarities and differences in their peptide-binding motifs. To investigate a possible categorization of HLA-DP molecules based on overlap of presented peptides, we identified and compared the peptidomes of the thirteen most frequently expressed HLA-DP molecules. Our categorization based on shared peptides was in line with the DPC classification. We found that the HLA-DP molecules within the previously defined groups DPC-1 or DPC-3 shared the largest numbers of presented peptides. However, the HLA-DP molecules in DPC-2 segregated into two subgroups based on the overlap in presented peptides. Besides overlap in presented peptides within the DPC groups, a substantial number of peptides was also found to be shared between HLA-DP molecules from different DPC groups, especially for groups DPC-1 and -2. The functional relevance of these findings was illustrated by demonstration of cross-reactivity of allo-HLA-DP-reactive T-cell clones not only against HLA-DP molecules within one DPC group, but also across different DPC groups. The promiscuity of peptides presented in various HLA-DP molecules and the cross-reactivity against different HLA-DP molecules demonstrate that these molecules cannot be strictly categorized in immunogenicity groups.

Indexed as

Graft vs Host DiseaseHLA-DP AntigensGraft vs Leukemia EffectHumansPeptidesT-LymphocytesHLA-DP AntigensPeptidesAlloSCTCD4 T-cell clonescross-reactivityDPC-classificationHLA-DPpeptidome

Identifiers

PMID35251023
PMCPMC8888658
OpenAlexW4213308044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.